Estados Unidos · Bolsa y Finanzas · Reuters Business

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

Publicado por Reuters Business · Estados Unidos hace 13 h

Australia's CSL said on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to ‌co-develop and co-promote a treatment for rare kidney and liver…

Leer el artículo completo en Reuters Business Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.reuters.com)

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

También te puede interesar

Russia hospitalizes almost 200 people after researcher's death from plague: reports

Zcash gets a Washington lobbyist to push crypto policy

Air Force removes all bombers from British base and redeploys them to the U.S. after a planned terror attack linked to Iran was foiled

Fuel Price Shock Pushes Global Gas Car Sales Below 50% for First Time

P.&G.’s Chief on Whether Brand Loyalty Is Enough When Prices Keep Climbing

Sam Altman said 'the world should accept some bad things happening' for the benefits of AI

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis

Compartir

También te puede interesar

Russia hospitalizes almost 200 people after researcher's death from plague: reports

Zcash gets a Washington lobbyist to push crypto policy

Air Force removes all bombers from British base and redeploys them to the U.S. after a planned terror attack linked to Iran was foiled

Fuel Price Shock Pushes Global Gas Car Sales Below 50% for First Time

P.&G.’s Chief on Whether Brand Loyalty Is Enough When Prices Keep Climbing

Sam Altman said 'the world should accept some bad things happening' for the benefits of AI